ESR1 mutations are observed mainly in metastatic HR+ breast cancers that have previously been treated with hormone therapy29, and all mutations affect the ligand-binding domain of the receptor, especially involving amino acids 537 or 538 in helix 1229. This evidence concerns the gene ESR1 and breast carcinoma.